

DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS*

3392. Adulteration and misbranding of amphetamine hydrochloride tablets. U. S. v. Robert Brinton Morris (Uno Laboratories). Plea of not guilty subsequently retracted. Fine of \$100 on count 1; imposition of sentence on count 2 suspended and defendant placed on probation for 2 years. (F. D. C. No. 29452. Sample No. 46720-K.)

INFORMATION FILED: August 8, 1950, District of New Jersey, against Robert Brinton Morris, trading as Uno Laboratories, at Pitman, N. J.

ALLEGED SHIPMENT: On or about May 7, 1949, from the State of New Jersey into the State of West Virginia.

LABEL, IN PART: (One bottle) "N-Methyl Amphetamine HCL (dl-Desoxyephedrine HCL) 10 Mgm. per Tablet"; (remainder of bottles) "Amphetamine HCL Tablets 10 Mgm. per Tablet."

NATURE OF CHARGE: Adulteration, Section 501 (d) (2), the tablets each containing 9.64 milligrams of racemic desoxyephedrine hydrochloride and containing no amphetamine hydrochloride had been substituted in whole or in part for tablets each containing 10 milligrams of amphetamine hydrochloride, which the article purported and was represented to be.

Misbranding, Section 502 (a), the label statements "N-Methyl Amphetamine HCL (dl-Desoxyephedrine HCL 10 Mgm. per Tablet" and "Amphetamine HCL Tablets 10 Mgm. per Tablet" were false and misleading since the tablets of the article contained no amphetamine hydrochloride.

DISPOSITION: April 20, 1951. A plea of not guilty having been retracted, the court imposed a fine of \$100 on count 1, suspended the imposition of sentence on count 2, and placed the defendant on probation for 2 years.

3393. Adulteration and misbranding of Conjugestoral tablets. U. S. v. 1 Bottle * * *. (F. D. C. No. 30765. Sample No. 4991-L.)

LABEL FILED: March 7, 1951, District of Massachusetts.

ALLEGED SHIPMENT: On or about October 14, 1950, by Corby-Franklin Associates, from New York, N. Y.

PRODUCT: 1 1,000-tablet bottle of *Conjugestoral tablets* at Brighton, Mass.

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the article differed from that which it was represented to possess, namely, 1.25 mg. of estrogens in their naturally occurring water-soluble conjugated form expressed as sodium estrone sulfate.

Misbranding, Section 502 (a), the label statement "Each tablet contains 1.25 mgm. of Estrogens in their naturally occurring water soluble conjugated form expressed as sodium estrone sulfate" was false and misleading as applied to the product, which contained less than the stated amount of estrogens.

DISPOSITION: April 23, 1951. Default decree of condemnation and destruction.

3394. Adulteration and misbranding of prophylactics. U. S. v. 42 Cartons * * *. (F. D. C. No. 30759. Sample Nos. 1494-L to 1496-L, incl.)

LABEL FILED: On or about March 13, 1951, Northern District of Georgia.

*See also No. 3385.